Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners

  • Linkedbio Partnering:

    Lingmed analyst team evaluates the innovative biotech products, technologies and medical devices to estimate the market size, risk & opportunities, to identify the right partner for the asset. Lingmed team will arrange partnering meetings to facilitate the direct dialogues, suggest deal structure to support deal closing

  • Linkedbio Analysis:

    Lingmed analyst team conducts desk researches and interviews to get insights on China market, we provide tailored product China market sizing analysis, deal valuation and competitive landscape reports to our clients

Latest Lingmed asset recommendation
European Innovative Autoimmune Disease Project – Treatment for Rheumatoid Arthritis (RA) Seeking Partners in China (LMP2795) (Monday, 10 Nov 2025)
  • Project ID: LMP2795
  • Epidemiology of Rheumatoid Arthritis
  • Current Treatment Status of Rheumatoid Arthritis
  • Lingmed Recommendation – Rheumatoid Arthritis Project：Project Description，Indications，Development Phase，Administration Route，Partnership Goal，Company Overview, Project Highlights......
Related asset recommendations
European innovative immuno-oncology project seeks global collaboration in the treatment of hematological tumors (LMP2789)
European Innovative Oncology Immunotherapy Project Seeking Chinese Partnerships (LMP2790)
Latest Lingmed monthly webinar
Analysis of drug targets and key pharmaceutical companies in pain therapeutic area, are you ready? (Thursday, 14 Nov 2024)
Event details
  • Potential innovative targets for new pain drugs
  • Breakthroughs and innovations of non-addictive pain drugs
  • Competition landscape of the top 10 domestic companies in pain therapeutic area
  • An innovative biotech roadshow
Related monthly webinars
Application of nano-antibodies in autoimmune diseases, are you ready?
Breakthroughs & progress of antiepileptic drugs, are you ready?
General information
Product > 454
Company > 830
Deals > 391
Reports > 175
Non-confi PDF > 192